Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ARGX stock, giving a Buy rating on February 28.
Thomas Smith has given his Buy rating due to a combination of factors that highlight Argenx Se’s strong financial performance and promising future prospects. The company reported fourth-quarter 2024 financial results that exceeded expectations, driven by robust sales of Vyvgart, particularly in the treatment of generalized myasthenia gravis and the early success in chronic inflammatory demyelinating polyneuropathy. This consistent commercial momentum has been a key factor in the positive outlook.
Additionally, the upcoming regulatory review for Vyvgart Hytrulo’s pre-filled syringe, with a PDUFA date set for April 2025, presents a significant opportunity for Argenx Se. The positive CHMP opinion for Vyvgart in Europe further strengthens their position. The year 2025 is expected to be pivotal, with multiple clinical milestones anticipated, including data from studies on efgart and empasiprubart. These developments, coupled with the company’s strategic plans and execution, reinforce its potential for growth and justify the Buy rating.
According to TipRanks, Smith is a top 100 analyst with an average return of 35.8% and a 48.45% success rate. Smith covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Argenx Se, and Celldex.
In another report released on February 28, JMP Securities also reiterated a Buy rating on the stock with a $701.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com